TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04027062

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Continuing Education Intervention
Description: The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians.
Study: NCT02959320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Hemiarthroplasty
Description: This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Hemiarthroplasty
Description: This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
Study: NCT01925534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow humidified nasal oxygen delivery system
Description: During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Description: During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
Study: NCT03982407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET/MRI
Description: The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
Study: NCT00957970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemless femoral component
Description: Total hip femoral component anatomically designed for a proximal fit without a stem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPS, Depuy cementless femoral stem
Description: Anatomical proximal fitted cementless stemmed femoral component
Study: NCT03077243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment for surgical evaluation
Description: Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
Study: NCT02793089

Intervention type: OTHER
Intervention: Analysis of Ectopic Pregnancy incidence
Description: Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)

Intervention type: OTHER
Intervention: Analysis of Ectopic Pregnancy incidence
Description: Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)

Intervention type: OTHER
Intervention: Analysis of Ectopic Pregnancy incidence
Description: Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)

Intervention type: OTHER
Intervention: Analysis of Ectopic Pregnancy incidence
Description: Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
Study: NCT03326661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: Needle aspiration of pus from the peritonsilar abscess

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy a chaud
Description: Removal of tonsil(s) due to peritonsillar abscess
Study: NCT04801199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
Study: NCT01943994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted treatment
Description: Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Study: NCT04408872

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Esophago-gastro-duodenoscopy (EGD)
Description: EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Description: EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
Study: NCT01075152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nucleoside
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nucleoside
Description: Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
Study: NCT03326661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)
Description: patients treated with aspiration will receive antibiotic treatment
Study: NCT01250743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid (vitamin C)
Description: intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
Study: NCT03269136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 monotherapy IV or SC
Description: PF-06863135 will be administered intravenously or subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 + dexamethasone
Description: PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 + lenalidomide
Description: PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06863135 + pomalidomide
Description: PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
Study: NCT03664635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
Study: NCT02790684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Study: NCT00145197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving the Delivery of Effective Care to Minorities
Description: The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
Study: NCT02650440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel Protocol
Description: All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Protocol
Description: All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
Study: NCT01511991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane dosage titration
Description: comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
Study: NCT00004180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Study: NCT00931060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids
Description: Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
Study: NCT00004180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Study: NCT04185051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67953964
Description: Participants will receive JNJ-67953964 as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67953964
Description: Participants will receive JNJ-67953964 as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo oral capsules.
Study: NCT02195089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLS_ILS_E710c 500mg
Description: - 2 capsules per day for 20 days (week 1,2,4 \& 8)
Study: NCT02761616

Intervention type: OTHER
Intervention: eBC treated participants
Description: No intervention administered in this retrospective observational study.
Study: NCT03182816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CTLA-4/PD-1 expressing EGFR-CAR-T
Description: Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
Study: NCT00504322

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: AdcuCD40L
Description: Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be the salt water-sugar solution used as a vehicle for the vector.
Study: NCT02195089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLS_ILB_710c 1000mg
Description: - 4 capsules per day for 20 days (week 1,2,4 \& 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLS_ILS_E710c 1500mg
Description: - 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
Study: NCT01673438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldoxorubicin
Study: NCT00311402

Intervention type: DRUG
Group type: OTHER
Intervention: Aggrenox capsule
Description: extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily

Intervention type: OTHER
Group type: OTHER
Intervention: Acetylsalicylic Acid (ASA)
Description: Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
Study: NCT03568279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust
Description: The assistant applied two-handed jaw thrust for intubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The intubation was done without two-handed jaw thrust.
Study: NCT01476618

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT03093428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
Study: NCT03506906

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sleep studies under noninvasive ventilation therapy
Description: Polysomnography Transcutaneous capnography
Study: NCT00698776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monocyte derived DCs loaded with KRN7000
Description: 10 million DCs injected intravenously
Study: NCT03093428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
Study: NCT02427867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Study: NCT03506906

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine tests
Description: Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
Study: NCT02200211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad®
Description: Binocular therapy on iPad®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching 2 hours per day, 7 days per week
Study: NCT02414997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
Study: NCT00956020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin matrix
Description: Single treatment with platelet rich fibrin matrix
Study: NCT02427867

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no ischemic preconditioning
Study: NCT01190020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubiprostone Control
Description: Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
Study: NCT02967770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecularly Tailored Second Line Therapy
Description: This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Second Line Therapy
Study: NCT02829775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Participants will maintain the same dose they were receiving in the parent protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa 2a
Description: Participants will maintain the same dose they were receiving in the parent protocol.
Study: NCT02788591

Intervention type: DRUG
Group type: OTHER
Intervention: Proton Pump Inhibitor (PPI) Therapy
Description: Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Sucralfate
Description: Subject will take Sucralfate 4 times a day for 8 weeks.
Study: NCT02212080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1214784
Description: Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
Study: NCT03506906

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine tests
Description: Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
Study: NCT00015340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Study: NCT02890654

Intervention type: OTHER
Intervention: First time measure
Description: * Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale

Intervention type: OTHER
Intervention: Second time measure
Description: * Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale

Intervention type: OTHER
Intervention: Third time measure
Description: * Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review